All In Biotech

Drug Trial Radar · NCT07191353

Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Oct 20, 2025

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Lead sponsor
Odense University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bispebjerg Hospital
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 60 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years. The main questions it aims to answer are: Can rapamycin's analog (Everolimus), resistance training, or their combination, enhance bone formation and muscle functions in elderly women compared to non-treatment controls. Participants will be randomized 1:1:1:1 to one of the following treatment regimens: * Oral everolimus 5 mg once a week. * Oral placebo once a week. * Oral everolimus 5 mg once a week plus resistance training RT 1 hour, 3 times weekly. * Oral placebo once a week plus resistance training RT 1 hour, 3 times weekly. During the study there will be a total of 5-7 visits, where the participants will undergo the following: * Blood samles * DXA-, HRpQCT- (only Odense Universitetshospital) and MRI-scans * Muscle- and bone biopsies * Quality of life questionnaires * Testing of muscle funtion * Metabolic studies of muscle and bone protein turnover using labelling with deuturated water

Conditions

  • Healthy
  • Osteopenia
  • Osteoporosis Risk

Interventions

  • EverolimusDrug

    Everolimus 5 mg administered once weekly for 24 weeks

  • PlaceboDrug

    Placebo administered once weekly for 24 weeks

  • Resistance trainingOther

    Resistance training 3 times a week for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. P1NPTime frame: From baseline to end of treatment at 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Institute of Sports Medicine, Bispebjerg Hospital

    Bispebjerg, Region Sjælland, Denmark · Recruiting

  • Department of Endocrinology, Odense University Hospital

    Odense, Region Syddanmark, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.